scholarly journals A prospective study comparing injectable interferon beta-1a (Rebif 22-44), (Avonex 30) and 1b (Betaseron 250) injection site reaction in multiple sclerosis patients

10.19082/7574 ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 7574-7579
Author(s):  
Foziah Jabbar Alshamrani ◽  
Hind Alnajashi ◽  
Fahad Alkhamis ◽  
Ibrahim Alghanimi ◽  
Abdulla Alsulaiman ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Prospective Study ◽  
Injection Site ◽  
Interferon Beta ◽  
Injection Site Reaction ◽  
Site Reaction ◽  
Multiple Sclerosis Patients ◽  
A Prospective Study

scholarly journals A Topical Adhesive Containing Anesthetic and Heating Components to Reduce Injection Pain with Subcutaneous Multiple Sclerosis Medications

2017 ◽  
Vol 19 (2) ◽  
pp. 85-90
Author(s):  
Theodore R. Brown ◽  
Virginia I. Simnad
Keyword(s):  
Multiple Sclerosis ◽  
Injection Site ◽  
Interferon Beta ◽  
Injection Site Reaction ◽  
Local Injection ◽  
Injection Pain ◽  
Site Reaction ◽  
Drug Injection ◽  
Randomized Controlled Studies ◽  
Scale Scores

Background: Injection pain and fear of pain are common with subcutaneous medications for treating multiple sclerosis (MS). Synera is a peel-and-stick topical adhesive (S-TA) with a novel heating component to enhance the delivery of an anesthetic mixture of lidocaine and tetracaine. We studied the effect of S-TA on pain and other aspects of comfort after subcutaneous MS drug injection. Methods: Thirty participants with MS having injection reactions to subcutaneous interferon beta (IFNβ) or glatiramer acetate (GA) were enrolled in an open-label prospective study. We captured six to seven injections at baseline and with 60- and 30-minute S-TA application times. The primary outcome was immediate pain on injection. Secondary outcomes included 12- and 24-hour pain ratings, 24-hour local injection-site reaction scale scores, 24-hour tenderness, and fear of injection (FOI). Results: Twenty-nine participants completed the study (interferon beta = 4, GA = 25, mean age = 51 years, females = 86%). There were significant reductions in injection pain, pain at 12 and 24 hours, tenderness at 24 hours, local injection-site reaction scale scores, and FOI for the 30- and 60-minute applications of S-TA (all P < .01). Results were similar in the GA subgroup. Adverse events included muscle spasm and lightheadedness (n = 1) and mild dermatitis (n = 1). Conclusions: These results suggest that S-TA applied 30 or 60 minutes before MS drug injection may reduce pain, tenderness, and FOI. Randomized controlled studies are needed to confirm the efficacy of ST-A.

scholarly journals Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Farida van Rey ◽  
John Heesakkers
Keyword(s):  
Multiple Sclerosis ◽  
Side Effects ◽  
Overactive Bladder ◽  
Prospective Study ◽  
Outcome Measure ◽  
Dose Increase ◽  
Neurogenic Disease ◽  
Multiple Sclerosis Patients ◽  
A Prospective Study ◽  
Disease Specific

Objective. To assess the efficacy and the effect on Qol of solifenacin for the treatment of OAB in MS patients.Patients and Methods. Thirty MS patients suffering from OAB were treated with solifenacin 5/10 mg for 8 weeks. The first 4 weeks patients received solifenacin 5 mg. At week 4 patients could request a dose increase to 10 mg. The efficacy was evaluated at 8 weeks.Results. After 4 weeks of treatment, 28 patients reported acceptable or no side effects. 17 continued the study with the 10 mg dosage, and 11 stayed on 5 mg solifenacin. Two patients withdrew from the study due to side effects. Solifenacin 5/10 mg for 8 weeks resulted in a significant decrease in number of micturitions and number of pads used per day compared to baseline. Also the severity of urgency prior to voiding decreased significantly, and an increase was seen in the volume per void. Twenty out of 30 patients chose to continue solifenacin therapy after termination of the study. The majority of patients reported global QoL improvement.Conclusions. Solifenacin is effective in the treatment of MS patients with OAB symptoms. This is the first study with solifenacin in a specific neurogenic patient group with a neurogenic disease-specific QoL outcome measure (MS-QoL 54).

Interferon-beta injection site reaction: Review of the histology and report of a lupus-like pattern

2008 ◽  
Vol 59 (2) ◽  
pp. S48-S49 ◽  
Author(s):  
Michael Conroy ◽  
Lindsay Sewell ◽  
O. Fred Miller ◽  
Tammie Ferringer
Keyword(s):  
Injection Site ◽  
Interferon Beta ◽  
Injection Site Reaction ◽  
Site Reaction
Sign in / Sign up

Export Citation Format

Share Document